LONDON, March 17, 2010 /PRNewswire/ -- Hikma
Pharmaceuticals today announced 2009 preliminary results with
operating profits up 36% on the back of a strong performance from
its Middle East markets.
In a video interview on financial broadcaster
http://www.cantos.com, Group CEO Said
Darwazah re-committed to his target of doubling the size of
the business every four years, saying, "If you look at our track
record over the last 10 or 12 years you see that we've pretty much
delivered that and I see no reason why we won't be able to continue
delivering that. So my commitment stands."
The emerging markets-based Pharma company also reported a return
to profitability in its US generics business and improving trends
in its European Injectables and Oncology businesses
Hikma also has a $300m dollar war
chest for acquisitions. Group Chief Financial Officer, Bassam Kanaan, said: "We have up to about
$300m of borrowing capacity which we
can use to fund acquisitions that we plan to make, especially in
the MENA region. Anything above that, I think we will have to
explore other options for funding."
The interviews and transcripts are available now on
http://www.cantos.com.
Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company
executives. If you would like to contact us, please email
amanda.alexander@cantos.com or phone +44-207-936-1352.